Appointments

866.320.4573

Submit a Form

Questions

800.223.2273

Submit a Form

Expand Content

A. Michael Lincoff, MD

216.444.6697

A. Michael Lincoff, MD
Department: Cardiovascular Medicine
Location: Cleveland Clinic Main Campus
Mail Code J2-3
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6697
DeskDesk:216.444.6740
WorkFax:216.445.6185
A. Michael Lincoff, MD
Department: Molecular Cardiology
Location: Cleveland Clinic Main Campus
Mail Code J2-3
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6697
DeskDesk:216.444.6740
WorkFax:216.445.6185
A. Michael Lincoff, MD
Department: Critical Care Center
Location: Cleveland Clinic Main Campus
Mail Code J2-3
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6697
DeskDesk:216.444.6740
WorkFax:216.445.6185
A. Michael Lincoff, MD
Department: Lerner Research Institute
Vice Chair for Clinical Research
Location: Cleveland Clinic Main Campus
9500 Euclid Avenue
Cleveland, OH 44195
WorkAppointment:216.444.6697
DeskDesk:216.444.6740
WorkFax:216.445.6185
Surgeon:
No
Treats:
Adults Only

Biographical Sketch

A. Michael Lincoff, MD, is Vice Chairman of the Robert and Suzanne Tomsich Department of Cardiovascular Medicine and an interventional cardiologist in the Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic.

He supervises clinical research activities throughout the Cleveland Clinic as Director of the Center for Clinical Research of the Lerner Research Institute. Dr. Lincoff is also the Director of the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), an academic research organization that plans, coordinates and manages multicenter clinical trials of new pharmacologic or device therapies.

Dr. Lincoff’s research activities focus on development of therapies to reduce acute and long-term complications of percutaneous coronary revascularization procedures, to optimize therapy for acute coronary ischemic syndromes or reduce progression or complications of atherosclerosis. He has served as principal investigator or steering committee member of over 15 pivotal trials in ischemic heart disease, enrolling in aggregate over 50,000 patients, studying new antiplatelet or antithrombotic agents in the settings of coronary intervention, heart attack or unstable angina.

Dr. Lincoff is a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. He holds the Charles and Charlotte Fowler Endowed Chair for Cardiovascular Research at Cleveland Clinic.

Dr. Lincoff has authored or coauthored over 200 peer-reviewed articles, including publications in the New England Journal of Medicine, Journal of the American Medical Association, Lancet, Annals of Internal Medicine, Circulation, Journal of the American College of Cardiology, American Heart Journal and European Heart Journal. He is editor of a book entitled Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease, now in its second edition. He has also authored over 80 book chapters and reviews and presented over 300 lectures at various medical meetings and courses throughout the world. He is the Consulting Editor of the American Journal of Cardiovascular Drugs and serves on editorial boards or as a reviewer for over 15 peer-reviewed scientific journals.

Dr. Lincoff is currently chairman of the Cardiovascular and Renal Drugs Advisory Committee of the United States Food and Drug Administration.

Dr. Lincoff is a fellow of the American College of Cardiology and the European Society of Cardiology and a member of the American College of Physicians, scientific councils of the American Heart Association and the Sigma Xi Scientific Research Society.

Professional Highlights

  • Director, Center for Clinical Research and Vice Chairman for Clinical Research of the Cleveland Clinic Lerner Research Institute
  • Director, Cleveland Clinic Coordinating Center for Clinical Research (C5Research)
  • Vice Chairman, Department of Cardiovascular Medicine, Cleveland Clinic
  • Charles and Charlotte Fowler Endowed Chair in Cardiovascular Research, Cleveland Clinic

Education & Fellowships

Fellowship - Cleveland Clinic
Interventional Cardiology
Cleveland, OH USA
1993
Fellowship - Cleveland Clinic
Cardiovascular Disease
Cleveland, OH USA
1992
Fellowship - University of Michigan Health System
Cardiovascular Medicine
Ann Arbor, MI USA
1991
Residency - Beth Israel Deaconess Medical Center and Harvard Medical School
Internal Medicine
Boston, MA USA
1989
Internship - Beth Israel Deaconess Medical Center and Harvard Medical School
Medical Internship
Boston, MA USA
1987
Medical School - Johns Hopkins University School of Medicine
Baltimore, MD USA
1986
Undergraduate - Carnegie Mellon University
Chemical/Biomed. Engineering
Pittsburgh, PA USA
1982

Certifications

  • Internal Medicine- Cardiovascular Disease
  • Internal Medicine
  • Internal Medicine- Interventional Cardiology

Specialty Interests

Coronary artery disease, heart attack, stent restenosis, total coronary occlusions, angioplasty, rotational atherectomy, stent-coronary, coronary artery atherectomy, coronary intervention, drug eluting stenting

Awards & Honors

Best Doctors, Cleveland magazine

Memberships

  • American College of Cardiology
  • European Society of Cardiology
  • American College of Physicians
  • American Heart Association
  • Sigma Xi Research Society

Treatment & Services

  • Abnormal Stress Test
  • Angiography
  • Angioplasty
  • Atherectomy
  • Clinical Trials
  • Coronary Balloon Angioplasty (PTCA)
  • Coronary Intervention
  • Drug Eluting Stenting
  • FFR determination
  • Intra-aortic Balloon Pumping
  • Rotational Atherectomy
  • Virtual Histology

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 5/7/2014, Dr. Lincoff has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Lincoff receives fees of $5,000 or more per year as a paid consultant, speaker or member of an advisory committee for the following companies:

  • WebMD

Charity. Dr. Lincoff has consulted for the following companies but instructed them to donate all compensation directly to one or more non-profit organizations:

  • CMEducation Resources, LLC

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.

Languages Spoken

  • English